

The Daily Extra, Financial News

Tunitas raises \$10M in series A

Published on Wednesday, September 30, 2015

Tunitas Therapeutics Inc. (San Francisco, Calif.) raised \$10 million in a series A round co-led by Ally Bridge Group and WuXi Ventures. RA Capital Advisors also participated.

Tunitas develops fusion proteins that target receptors activated by allergens. It is developing lead candidate epsi-gam, a fusion protein comprising the Fc portions of human IgE and IgG1, to treat asthma. CEO Nolan Sigal told BioCentury that Tunitas would start a Phase I trial of the candidate "soon" and that it hopes to begin a Phase IIa trial in 2016.

Tunitas' technology is based on research from the laboratory of Andrew Saxon at UCLA Medical Center. Saxon is Tunitas' acting CSO.

Sigal said the company received \$10 million in NIH funding prior to the venture round.

Tunitas is also developing preclinical vaccines against cat and peanut allergens.

David Nikodem of Ally Bridge and Sophie Qiao of WuXi Ventures joined the Tunitas board.

All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.